For research use only. Not for therapeutic Use.
SU11274（Cat No.:I013979）is a selective inhibitor of the MET receptor tyrosine kinase, which plays a crucial role in processes like cell growth, survival, and metastasis. By inhibiting MET, SU11274 disrupts key signaling pathways involved in tumor progression and invasion, particularly in cancers where MET is overexpressed or mutated, such as non-small cell lung cancer (NSCLC) and gastric cancer. SU11274 has shown potential in preclinical models by reducing cancer cell proliferation and enhancing the effectiveness of other cancer therapies. It is a valuable tool for exploring MET-targeted cancer treatments.
| Catalog Number | I013979 |
| CAS Number | 658084-23-2 |
| Molecular Formula | C₂₈H₃₀ClN₅O₄S |
| Purity | ≥95% |
| Target | c-Met/HGFRAutophagy |
| Solubility | 10 mM in DMSO |
| IUPAC Name | (3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide |
| InChI | InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16- |
| InChIKey | FPYJSJDOHRDAMT-KQWNVCNZSA-N |
| SMILES | CC1=C(NC(=C1C(=O)N2CCN(CC2)C)C)/C=C\3/C4=C(C=CC(=C4)S(=O)(=O)N(C)C5=CC(=CC=C5)Cl)NC3=O |
| Reference | [1]. Wang X, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther, 2003, 2(11):1085-1092.<br>[2]. Sattler M, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res, 2003, 63(17), 5462-5469.<br>[3]. Ma PC, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res, 2005, 65(4), 1479-1488. |
